Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 16,829 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 16,829 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $65.54, for a total transaction of $1,102,972.66. Following the completion of the transaction, the chief executive officer owned 2,003,213 shares in the company, valued at $131,290,580.02. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Tempus AI Stock Up 3.4%

Tempus AI stock opened at $67.91 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. Tempus AI, Inc. has a fifty-two week low of $31.36 and a fifty-two week high of $104.32. The firm has a fifty day moving average price of $83.96 and a two-hundred day moving average price of $71.87. The firm has a market cap of $12.08 billion, a price-to-earnings ratio of -57.07 and a beta of 4.86.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The business had revenue of $334.21 million for the quarter, compared to analyst estimates of $328.89 million. During the same period in the previous year, the company posted ($0.46) earnings per share. The firm’s revenue for the quarter was up 84.7% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. As a group, analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Cowen lowered Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. Canaccord Genuity Group dropped their target price on shares of Tempus AI from $110.00 to $95.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a report on Wednesday, October 8th. BTIG Research restated a “buy” rating and set a $96.00 price objective on shares of Tempus AI in a report on Wednesday, November 5th. Finally, TD Cowen lowered shares of Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 price objective for the company. in a research report on Tuesday, October 21st. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Tempus AI currently has a consensus rating of “Hold” and an average target price of $80.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. EMC Capital Management acquired a new position in shares of Tempus AI in the 3rd quarter worth approximately $297,000. Sunbelt Securities Inc. bought a new position in Tempus AI in the third quarter valued at approximately $52,000. Captrust Financial Advisors grew its holdings in Tempus AI by 24.8% during the 3rd quarter. Captrust Financial Advisors now owns 135,066 shares of the company’s stock worth $10,901,000 after acquiring an additional 26,853 shares during the period. Danske Bank A S bought a new stake in Tempus AI in the third quarter valued at about $48,000. Finally, Advisory Services Network LLC acquired a new stake in shares of Tempus AI in the 3rd quarter valued at approximately $256,000. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.